Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.

dc.contributor.author

Zhao, Fei

dc.contributor.author

Xiao, Christine

dc.contributor.author

Evans, Kathy S

dc.contributor.author

Theivanthiran, Tbalamayooran

dc.contributor.author

DeVito, Nicholas

dc.contributor.author

Holtzhausen, Alisha

dc.contributor.author

Liu, Juan

dc.contributor.author

Liu, Xiaojing

dc.contributor.author

Boczkowski, David

dc.contributor.author

Nair, Smita

dc.contributor.author

Locasale, Jason W

dc.contributor.author

Hanks, Brent A

dc.date.accessioned

2018-12-02T19:51:41Z

dc.date.available

2018-12-02T19:51:41Z

dc.date.issued

2018-01

dc.date.updated

2018-12-02T19:51:33Z

dc.description.abstract

Despite recent advances, many cancers remain refractory to available immunotherapeutic strategies. Emerging evidence indicates that the tolerization of local dendritic cells (DCs) within the tumor microenvironment promotes immune evasion. Here, we have described a mechanism by which melanomas establish a site of immune privilege via a paracrine Wnt5a-β-catenin-peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling pathway that drives fatty acid oxidation (FAO) in DCs by upregulating the expression of the carnitine palmitoyltransferase-1A (CPT1A) fatty acid transporter. This FAO shift increased the protoporphyrin IX prosthetic group of indoleamine 2,3-dioxgenase-1 (IDO) while suppressing interleukin(IL)-6 and IL-12 cytokine expression, culminating in enhanced IDO activity and the generation of regulatory T cells. We demonstrated that blockade of this pathway augmented anti-melanoma immunity, enhanced the activity of anti-PD-1 antibody immunotherapy, and suppressed disease progression in a transgenic melanoma model. This work implicates a role for tumor-mediated metabolic reprogramming of local DCs in immune evasion and immunotherapy resistance.

dc.identifier

S1074-7613(17)30533-2

dc.identifier.issn

1074-7613

dc.identifier.issn

1097-4180

dc.identifier.uri

https://hdl.handle.net/10161/17695

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Immunity

dc.relation.isversionof

10.1016/j.immuni.2017.12.004

dc.subject

Dendritic Cells

dc.subject

Cell Line

dc.subject

Animals

dc.subject

Mice, Transgenic

dc.subject

Mice

dc.subject

Melanoma

dc.subject

Fatty Acids

dc.subject

PPAR gamma

dc.subject

Immunoblotting

dc.subject

Enzyme-Linked Immunosorbent Assay

dc.subject

Flow Cytometry

dc.subject

Polymerase Chain Reaction

dc.subject

Paracrine Communication

dc.subject

Signal Transduction

dc.subject

Female

dc.subject

Male

dc.subject

beta Catenin

dc.subject

Wnt-5a Protein

dc.title

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.

dc.type

Journal article

duke.contributor.orcid

DeVito, Nicholas|0000-0001-7537-8647

duke.contributor.orcid

Nair, Smita|0000-0001-7019-1912

duke.contributor.orcid

Locasale, Jason W|0000-0002-7766-3502

duke.contributor.orcid

Hanks, Brent A|0000-0002-2803-3272

pubs.begin-page

147

pubs.end-page

160.e7

pubs.issue

1

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Pathology

pubs.organisational-group

Neurosurgery

pubs.organisational-group

Surgery, Surgical Sciences

pubs.organisational-group

Surgery

pubs.publication-status

Published

pubs.volume

48

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Brent Hanks_2018 Immunity.pdf
Size:
5.06 MB
Format:
Adobe Portable Document Format
Description:
Accepted version